Rise and Fall of Valeant

Money Talking | Mar 18, 2016

The pharmaceutical company Valeant is in big trouble. 

As recently as last summer, Valeant was admired on Wall Street and its stock traded above $250 a share. But since then, the share price has plummeted, and after a difficult earnings announcement this week where CEO Michael Pearson revealed that it will not file its annual report on time, its stock sunk to just above $30 a share.

For years, the company had been steadily growing, buying other companies in addition to raising the prices of the drugs it acquired.

Now Valeant's business practices are under investigation by the Securities and Exchange Commission, two U.S. Attorneys, and Congress.

This week on Money Talking, host Charlie Herman talks with Bloomberg Businessweek's Sheelah Kolhatkar and Linette Lopez with Business Insider to explore the Valeant bust and how it affects what you pay for your prescriptions.

Be alert for scams. WNYC never asks for nor accepts money for coverage or interviews. Anyone making such a request does not represent WNYC.

Top Stories

With search for victims over, NYC officials look to what caused fatal building collapse

Exclusive video shows shocking moment Brooklyn building collapsed

Speaker Heastie on the Next Term

Advice for Being a Good Friend

YOU ARE ONLINE